Literature DB >> 10385321

Improving antibody affinity by mimicking somatic hypermutation in vitro.

P S Chowdhury1, I Pastan.   

Abstract

In vivo affinity maturation of antibodies involves mutation of hot spots in the DNA encoding the variable regions. We have used this information to develop a strategy to improve antibody affinity in vitro using phage display technology. In our experiment with the antimesothelin scFv, SS(scFv), we identified DNA sequences in the variable regions that are naturally prone to hypermutations, selected a few hot spots encoding nonconserved amino acids, and introduced random mutations to make libraries with a size requirement between 10(3) and 10(4) independent clones. Panning of the hot spot libraries yielded several mutants with a 15- to 55-fold increase in affinity compared with a single clone with a fourfold increased affinity from a library in which mutagenesis was done outside the hot spots. The strategy should be generally applicable for the rapid isolation of higher-affinity mutants of Fvs, Fabs, and other recombinant antibodies from antibody phage libraries that are small in size.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385321     DOI: 10.1038/9872

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  68 in total

1.  By-passing selection: direct screening for antibody-antigen interactions using protein arrays.

Authors:  L J Holt; K Büssow; G Walter; I M Tomlinson
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

2.  Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.

Authors:  Mitchell Ho; Mariangela Segre
Journal:  Biochim Biophys Acta       Date:  2003-07-30

Review 3.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

4.  Development of a novel mammalian cell surface antibody display platform.

Authors:  Chen Zhou; Frederick W Jacobsen; Ling Cai; Qing Chen; Weyen David Shen
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

5.  Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.

Authors:  Changming Yu; Gennett M Pike; Tommy A Rinkoski; Cristina Correia; Scott H Kaufmann; Mark J Federspiel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

6.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

7.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries.

Authors:  Arvind Rajpal; Nurten Beyaz; Lauric Haber; Guido Cappuccilli; Helena Yee; Ramesh R Bhatt; Toshihiko Takeuchi; Richard A Lerner; Roberto Crea
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

8.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

9.  Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy.

Authors:  Warren D Marcus; Hongda Wang; Stuart M Lindsay; Michael R Sierks
Journal:  Nanomedicine       Date:  2008-01-16       Impact factor: 5.307

Review 10.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.